Interestingly, an increase in CD45+CK- cells consistent with tumor-infiltrating immune cells were observed in tumor tissues only in patients treated with the sapanisertib lead-in, and further increased with combination therapy in two of these patients, one who experienced progression as best response and one with stable disease (S-2 and S-4) (Figure 4A). This evidence concerns the gene PTPRC and neoplasm.